Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone

[1]  H. Hait,et al.  A multicenter, randomized study of an extended cycle oral contraceptive. , 2003, Contraception.

[2]  A. Rapkin,et al.  Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. , 2003, The Journal of reproductive medicine.

[3]  C. Gerlinger,et al.  Recommendation for confidence interval and sample size calculation for the Pearl Index , 2003, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[4]  D. Apter,et al.  Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms , 2003, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[5]  T. Kuehl,et al.  Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. , 2002, American journal of obstetrics and gynecology.

[6]  C. Gerlinger,et al.  The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. , 2002, Cutis.

[7]  H. Skarabis,et al.  The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[8]  R Krattenmacher,et al.  Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. , 2000, Contraception.

[9]  J. Foidart,et al.  A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[10]  A. Pong,et al.  An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. , 2000, Contraception.

[11]  M. Riggs,et al.  Hormone Withdrawal Symptoms in Oral Contraceptive Users , 2000, Obstetrics and gynecology.

[12]  J. Foidart,et al.  Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone , 2000, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

[13]  D. Archer,et al.  Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®) , 1999 .

[14]  C. Gerlinger,et al.  Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. , 1999, Contraception.

[15]  M. Rosenberg,et al.  Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. , 1998, American journal of obstetrics and gynecology.

[16]  D. Archer,et al.  A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg , 1997 .

[17]  D. Archer,et al.  A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms. North American Levonorgestrel Study Group (NALSG). , 1997, Contraception.

[18]  J. Endrikat,et al.  A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, with respect to efficacy, cycle control, and tolerance. , 1995, Contraception.

[19]  W. Feichtinger,et al.  Shorter pill-free interval in combined oral contraceptives decreases follicular development. , 1996, Contraception.

[20]  M. Åkerlund,et al.  Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol , 1993 .

[21]  T. Farley,et al.  The analysis of menstrual bleeding patterns: a review. , 1988, Contraception.

[22]  D. Machin,et al.  The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. , 1986, Contraception.

[23]  E. Diczfalusy.  World Health Organization. Special programme of research, development and research training in human reproduction. The first fifteen years: a review. , 1986, Contraception.

[24]  M. Vessey,et al.  A RANDOMIZED DOUBLE‐BLIND TRIAL OF TWO LOW DOSE COMBINED ORAL CONTRACEPTIVES , 1979, British journal of obstetrics and gynaecology.